Search Results 1531-1540 of 19169 for Neutrophil

  1. Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma - Mayo Clinic

    absolute neutrophil count ≥ 1,500/mcL;; platelets ≥ 100,000/mcL;; total bilirubin Within normal institutional limits;; AST(SGOT)/ALT(SGPT) ≤ 2.5 ...

  2. Study of mouse gut microbiome may provide clues to how cancer develops in humans - Mayo Clinic News Network

    Joe Dangor, Mayo Clinic Public Affairs, newsbureau@mayo.edu · Caring at home for yourself and others suffering from COVID-19 · Science Saturday: Neutrophils may ...

  3. Publications - Pedro Horna, M.D. - Mayo Clinic

    Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology [Manuscript Accepted] Journal of Leukocyte Biology.2017;; Betts BC, Veerapathran A ...

  4. Chronic Lymphocytic Leukemia Clinical Trials - Mayo Clinic Research

    ... neutrophil cytoplasmic antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models. Study of Pembrolizumab (MK-3475) ...

  5. Sulfamethoxazole and trimethoprim (oral route) - Side effects & dosage - Mayo Clinic

    ... neutrophilic dermatosis (AFND). Check with your doctor if you have a skin rash, blistering, peeling, loosening of the skin, chills, cough, diarrhea, itching ...

  6. A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers - Mayo Clinic

    - Absolute neutrophil count >= 1,500/mcL - Hemoglobin >= 9.0 g/dl - Platelets >= 100,000/mcL - Total bilirubin =< 1.5 x institutional upper limit of normal ...

  7. Clinical trials - Oncology (Medical)

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a neutrophil ...

  8. Clinical trials - Oncology (Medical)

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a neutrophil ...

  9. Testing Teclistamab (TECVAYLI) In Combination With Iberdomide For Hard-to-Treat Multiple Myeloma - Mayo Clinic

    * Absolute neutrophil count ≥ 1,000/mcL ( ≤ 28 days prior to registration) (Without growth factor support, blood transfusion, or platelet stimulating ...

  10. MC230813 A Study of Golcadomide with Rituximab prior to CAR-T with Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL) - Mayo Clinic

    Absolute neutrophil count (ANC) ≥1000/mcL; growth factor support allowed at physician discretion. Platelet count ≥75,000/mcL; Total bilirubin ≤1.5 x ULN ...